Brief: GRI Bio Bolsters Patent Portfolio
27/06/2023 14:27
June 27 (Reuters) - GRI Bio Inc GRI.O :
* GRI BIO INC - U.S. PATENT ISSUANCE FOR LEAD PROGRAM,
GRI-0621,IN
DEVELOPMENT FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
* GRI BIO - PLANS TO LEVERAGE 505(B)(2) REGULATORY PATHWAY &
LAUNCH PHASE 2A BIOMARKER STUDY EVALUATING GRI-0621 FOR
TREATMENT OF IPF IN H2 OF 2023
Source text for Eikon: ID:nGNX9JbCyg
Further company coverage: GRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027